REC-1245

About Recursion Pharmaceuticals

Recursion Pharmaceuticals is pioneering a TechBio approach to industrialize drug discovery, leveraging its proprietary Recursion OS—a closed-loop platform integrating automated wet labs, one of the world's largest fit-for-purpose biological datasets (>50 PB), and machine learning foundation models. The company has built a maturing clinical pipeline, with its lead asset, REC-4881 for Familial Adenomatous Polyposis (FAP), in Phase 2 and multiple other oncology programs in Phase 1/2. Its strategy centers on scaling its platform to systematically discover and develop first-in-class and best-in-class medicines, supported by strategic partnerships with pharmaceutical and technology leaders.

Therapeutic Areas